CSPC OUYI PHARMACEUTICAL CO., LTD.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-03-29
- Employees
- -
- Market Cap
- -
- Website
- http://www.e-cspc.com
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)
Phase 3
Not yet recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 454
- Registration Number
- NCT05753865
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijia Zhuang, Hebei, China
Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 367
- Registration Number
- NCT05728541
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
Phase 3
Completed
- Conditions
- Invasive CandidiasisInvasive Aspergillosis
- Interventions
- Drug: Amphotericin B cholesteryl Sulfate Complex for Injection
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05707832
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 139
- Registration Number
- NCT05609019
A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer
Phase 1
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: SYHX2011 and Abraxane®
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05274893
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer MetastaticPancreatic Cancer Non-resectable
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 153
- Registration Number
- NCT05047991
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Phase 2
Terminated
- Conditions
- Extrahepatic CholangiocarcinomaAdvanced Biliary Tract CancerGallbladder CarcinomaIntrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT05009953
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects
Phase 1
- Conditions
- Healthy Subjects
- Interventions
- Drug: SYHX 1901 tabletsDrug: Placebo
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT04880512
- Locations
- 🇨🇳
Huashan Hospital of Fudan University, Shanghai, China
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 119
- Registration Number
- NCT04728035
- Locations
- 🇨🇳
Cancer Hosptial of CAMS, Beijing, Beijing, China
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
Phase 2
Completed
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT04727853
- Locations
- 🇨🇳
Jilin Cancer Hospital, Chang Chun, Jilin, China
© Copyright 2025. All Rights Reserved by MedPath